| | |
PV1
|
PV2
|
PV3
|
|---|
|
No. of tested samples (%)
|
No. of positive samples (%)
|
P value*
|
No. of positive samples (%)
|
P value
|
No. of positive samples (%)
|
P value
|
|---|
|
Total
|
745
|
616 (82.7)
| |
685 (91.9)
| |
509 (68.3)
| |
|
Sex
| | | | | | | |
|
Male
|
349 (46.8)
|
289 (82.8)
|
0.51
|
314 (90.0)
|
0.04
|
236 (67.6)
|
0.38
|
|
Female
|
396 (53.2)
|
327 (82.6)
| |
371 (93.7)
| |
273 (68.9)
| |
|
Age (years)
| | | | | | | |
|
6–10 (IPV)
|
236 (31.7)
|
220 (93.2)
|
<0.01
|
228 (96.6)
|
<0.05
|
207 (87.7)
|
<0.01
|
|
11–20 (OPV)
|
216 (29.0)
|
173 (80.1)
| |
199 (92.1)
| |
126 (58.3)
| |
|
21–40 (OPV)
|
135 (18.1)
|
106 (78.5)
| |
122 (90.4)
| |
72 (53.3)
| |
|
41–60 (OPV)
|
113 (15.2)
|
79 (69.9)
| |
95 (84.1)
| |
74 (65.5)
| |
|
>60 (OPV)
|
45 (6.0)
|
38 (84.4)
| |
41 (91.1)
| |
30 (66.7)
| |
|
Region
| | | | | | | |
|
Gyeonggi-do
|
237 (31.8)
|
202 (85.2)
|
0.065
|
226 (95.4)
|
0.018
|
172 (72.6)
|
0.033
|
|
Gyeongsang-do
|
170 (22.8)
|
135 (79.4)
| |
154 (90.6)
| |
108 (63.5)
| |
|
Seoul
|
126 (16.9)
|
103 (81.7)
| |
114 (90.5)
| |
80 (63.5)
| |
|
Chungcheong-do
|
112 (15.0)
|
95 (84.8)
| |
101 (90.2)
| |
85 (75.9)
| |
|
Jeolla-do
|
68 (9.1)
|
54 (79.4)
| |
59 (86.8)
| |
42 (61.8)
| |
|
Gangwon-do
|
24 (3.2)
|
19 (79.2)
| |
23 (95.8)
| |
17 (70.8)
| |
|
Jeju-do
|
8 (1.1)
|
8 (100.0)
| |
8 (100.0)
| |
5 (62.5)
| |
- *P < 0.05 indicates significant differences of seroprevalence among the compared groups.
- IPV, inactivated poliovirus vaccine; OPV, oral poliovirus vaccine; PV, poliovirus.
